

## Special Issue

# The Interstitial Lung Diseases: From Pathogenesis to Therapy

### Message from the Guest Editors

The classification of interstitial lung diseases (ILDs) continues to evolve, but even with modern diagnosis techniques, some ILDs remain unclassifiable. On the other hand, many diseases which are not classified as ILDs (such as tuberculosis or COPD) have an interstitial component, which should receive further study so that appropriate treatment can be developed.

Recent advances in diagnosis and therapy have led to improved treatment, but only a comprehensive characterisation of the interstitial pathology, including etiological factors, biomarkers, phenotypes, and treatable traits, will allow for the introduction of precision medicine interventions.

We invite colleagues with an interest in this field of research to submit original research or review articles that contribute to the current body of knowledge on interstitial pathology, focusing in a broader sense on the pathogenic mechanisms that alter the interstitium. In this way, we hope to enhance the current understanding of the environmental and immunological factors of disease development and progression and the therapeutical approach.

---

### Guest Editors

Dr. Marina Ruxandra Otelea

Clinical Department 5, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania

Dr. Oana Cristina Arghir

Doctoral School of Medicine, Faculty of General Medicine, "Ovidius" University, 900470 Constanta, Romania

---

### Deadline for manuscript submissions

closed (30 April 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/128183](https://mdpi.com/si/128183)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).